As European markets navigate renewed trade and geopolitical uncertainty, with the pan-European STOXX Europe 600 Index ending 0.98% lower, investors are increasingly looking towards dividend stocks as a potential source of steady income amid market volatility. In such an environment, selecting dividend stocks that offer strong yields can be particularly appealing, especially those with a history of stable payouts and resilience in fluctuating economic conditions.

As European markets show signs of steady economic growth and benefit from looser monetary policies, investors may find opportunities in dividend stocks that offer attractive yields. In the current environment, focusing on companies with strong fundamentals and consistent dividend payouts can be a prudent strategy for those seeking income amid market fluctuations.

As the European markets navigate a landscape marked by stable growth in major indices and cautious optimism amidst interest rate assessments, investors continue to seek reliable avenues for income generation. In this context, dividend stocks stand out as a compelling choice, offering potential stability and income even as broader market conditions fluctuate.

As European markets navigate a complex landscape marked by mixed performances across major indices and cautious monetary policy decisions, investors are keenly assessing opportunities in the region's small-cap sector. In this environment, identifying promising stocks often involves looking for companies with strong fundamentals that can thrive despite economic uncertainties and interest rate fluctuations.

Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really happening beneath the surface. GL Events is one of those names where, if you had blinked a year ago, you might have missed some serious upside. Over the past five years, the stock has delivered a remarkable 219.9% return, and it is up 103.9% over three years alone. Even with a recent pullback of...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.